🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

BRIEF-J&J Anticipates Fulfilling 10 Million Doses Included In Advance Purchase Agreement With The Government Of Canada By The End Of Q3 2021

Published 2021-03-05, 10:40 a/m
© Reuters.
JNJ
-

March 5 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N :

* ANTICIPATES FULFILLING 10 MILLION DOSES INCLUDED IN ADVANCE PURCHASE AGREEMENT WITH THE GOVERNMENT OF CANADA BY THE END OF Q3 2021

* PLANS TO FILE FOR A NOTICE OF COMPLIANCE WITH HEALTH CANADA LATER IN 2021

* BEEN WORKING TO DEVELOP AND ACTIVATE MANUFACTURING CAPABILITIES FOR COVID-19 VACCINE, WHICH WILL ENABLE US TO MEET 2021 SUPPLY COMMITMENTS

* COVID-19 VACCINE SHOULD NOT BE RE-FROZEN IF DISTRIBUTED AT TEMPERATURES OF 2°-8°C

* COVID-19 VACCINE ESTIMATED TO REMAIN STABLE FOR 2 YEARS AT -20°C & MAXIMUM OF 3 MONTHS AT ROUTINE REFRIGERATION AT TEMPERATURES OF 2°C TO 8°C

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.